TROG Cancer Research
Members Login   CQMS Login  

Bladder, Kidney and Prostate trials now recruiting


TROG 15.03 (FASTRACKII) - this study aims to evaluate the activity and efficacy of Stereotactic Ablative Body Radiotherapy (SABR) for the treatment of kidney cancers.

Primary sponsor: TROG
Collaborating group:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)


TROG 15.01 (SPARK) - this trial is testing the use of Kilvoltage Intrafraction Monitoring (KIM) in prostate cancer patients being treated with Stereotactic Prostate Adaptive Radiotherapy. The researchers expect this trial to result in better targeted prostate cancer patient outcomes with lower toxicity.

Primary sponsor: University of Sydney
Collaborating groups: TROG


TROG 14.02 (RAIDER) - this international clinical trial plans to use daily imaging to determine the optimal radiation treatment for bladder cancer patients.

Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG


ANZUP 1303 (ENZARAD) - the study will compare the effectiveness of standard deprivation therapy and radiation therapy combined either with enzalutamide or currently available antiandrogen drugs for improving the survival in men with localised prostate cancer at high risk of recurrence.

Primary sponsor: ANZUP​
Collaborating group: TROG (TROG 14.01)

 

 

 

We are thankful to our 14,000 patients who have participated in our research. Please continue the generous support.